A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company Outset is a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity. We believe the Tablo® Hemodialysis System (Tablo) represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. We designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. Tablo is currently cleared by the U.S. Food and Drug Administration (FDA) for use in the hospital, clinic or home setting. Our technology is designed to elevate the dialysis experience for patients, and help providers overcome traditional care delivery challenges. Our focus on flexibility, ease of use, data analytics and user experience translates to meaningfully reduced training times and fixed infrastructure requirements.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 119M | 119M | 114M | 130M | 115M | 103M |
| Net Income | -82M | -82M | -128M | -173M | -163M | -132M |
| EPS | $-5.37 | $-5.37 | $-36.96 | $-52.20 | $-50.70 | $-43.35 |
| Free Cash Flow | -47M | -47M | -117M | -135M | -154M | -133M |
| ROIC | -28.0% | -36.6% | -57.1% | -68.3% | -47.6% | -32.7% |
| Gross Margin | 39.1% | 39.1% | 33.9% | 22.2% | 15.5% | 7.4% |
| Debt/Equity | 0.76 | 0.76 | 7.36 | 1.06 | 0.41 | 0.08 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -67M | -67M | -113M | -170M | -161M | -131M |
| Operating Margin | -55.8% | -55.8% | -99.7% | -130.2% | -139.6% | -127.2% |
| ROE | -64.3% | -106.2% | -477.2% | -140.6% | -66.2% | -35.3% |
| Shares Outstanding | 15M | 15M | 18M | 3M | 3M | 3M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15M | N/A | 103M | 115M | 130M | 114M | 119M | 119M |
| Gross Margin | -118.1% | N/A | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% | 39.1% |
| R&D | 23M | 29M | 37M | 49M | 57M | 38M | 21M | 21M |
| SG&A | 8.9M | 31M | 36M | 41M | 45M | 43M | 38M | 38M |
| EBIT | -70M | -117M | -131M | -161M | -170M | -113M | -67M | -67M |
| Op. Margin | -466.3% | N/A | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% | -55.8% |
| Net Income | N/A | -121M | -132M | -163M | -173M | -128M | -82M | -82M |
| Net Margin | N/A | N/A | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% | -68.3% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/A | -33.9% | -32.7% | -47.6% | -68.3% | -57.1% | -36.6% | -28.0% |
| ROE | N/A | -37.0% | -35.3% | -66.2% | -140.6% | -477.2% | -106.2% | -64.3% |
| ROA | N/A | -30.1% | -28.5% | -40.7% | -55.1% | -46.4% | -30.2% | -30.9% |
| Cash Flow | ||||||||
| Op. Cash Flow | -70M | -99M | -130M | -146M | -131M | -116M | -46M | -46M |
| Free Cash Flow | -74M | -108M | -133M | -154M | -135M | -117M | -47M | -47M |
| Owner Earnings | -73M | -124M | -153M | -178M | -176M | -151M | -66M | -66M |
| CapEx | 3.3M | 9.1M | 3.1M | 8.3M | 3.4M | 912K | 798K | 798K |
| Maint. CapEx | 1.5M | 3.2M | 5.2M | 5.2M | 5.8M | 5.7M | 4.3M | 4.3M |
| Growth CapEx | 1.8M | 5.9M | 0 | 3.2M | 0 | 0 | 0 | 0 |
| D&A | 1.5M | 3.2M | 5.2M | 5.2M | 5.8M | 5.7M | 4.3M | 4.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 883K | 21M | 17M | 27M | 39M | 29M | 16M | 16M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -34M | -278M | -308M | -186M | -73M | 39M | -73M | 61M |
| Cash & Equiv. | 37M | 295M | 182M | 73M | 69M | 124M | 35M | 35M |
| Long-Term Debt | 22M | 30M | 30M | 96M | 130M | 197M | 96M | 96M |
| Debt/Equity | -0.10 | 0.11 | 0.08 | 0.41 | 1.06 | 7.36 | 0.76 | 0.76 |
| Interest Coverage | -16.5 | -40.6 | -76.1 | -45.2 | -13.4 | -4.7 | -4.8 | -4.8 |
| Equity | -372M | 329M | 374M | 246M | 123M | 27M | 127M | 127M |
| Total Assets | 88M | 404M | 463M | 400M | 314M | 276M | 264M | 264M |
| Total Liabilities | 51M | 75M | 89M | 154M | 191M | 249M | 138M | 138M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -373M | -494M | -626M | -789M | -962M | -1.1B | -1.2B | -1.2B |
| Working Capital | 55M | 309M | 358M | 322M | 236M | 213M | 213M | 213M |
| Current Assets | 80M | 346M | 410M | 374M | 291M | 258M | 251M | 251M |
| Current Liabilities | 25M | 37M | 52M | 52M | 55M | 45M | 38M | 38M |
| Per Share Data | ||||||||
| EPS | -1,493.70 | -72.75 | -43.35 | -50.70 | -52.20 | -36.96 | -5.37 | -5.37 |
| Owner EPS | -25.46 | -74.02 | -50.23 | -55.41 | -53.11 | -8.27 | -4.36 | -4.36 |
| Book Value | -130.42 | 196.77 | 122.91 | 76.53 | 37.12 | 1.46 | 8.35 | 8.35 |
| Cash Flow/Share | -24.63 | -59.29 | -42.80 | -45.34 | -39.69 | -6.35 | -3.05 | -5.08 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.9M | 1.7M | 3.0M | 3.2M | 3.3M | 18.3M | 15.2M | 15.2M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 4.0 | 5.5 | 4.8 | 2.3 | 11.7 | 0.4 | 0.5 |
| Price/Sales | N/A | N/A | 22.0 | 11.1 | 6.3 | 5.7 | 1.7 | 0.6 |
| FCF Yield | N/A | -8.2% | -6.5% | -13.0% | -47.9% | -37.4% | -92.2% | -71.2% |
| Market Cap | N/A | 1.3B | 2.1B | 1.2B | 282M | 313M | 51M | 66M |
| Avg. Price | N/A | 775.69 | 740.78 | 398.67 | 248.92 | 35.56 | 13.07 | 4.35 |
| Year-End Price | N/A | 791.85 | 674.55 | 367.95 | 85.05 | 17.10 | 3.36 | 4.35 |
Outset Medical, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 23.6%.
Outset Medical, Inc. (OM) has a 5-year average return on invested capital (ROIC) of -48.4%. This is below average and may indicate limited pricing power.
Outset Medical, Inc. (OM) has a market capitalization of $66M. It is classified as a small-cap stock.
Outset Medical, Inc. (OM) does not currently pay a regular dividend.
Outset Medical, Inc. (OM) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Outset Medical, Inc. (OM) reported annual revenue of $119 million in its most recent fiscal year, based on SEC EDGAR filings.
Outset Medical, Inc. (OM) has a net profit margin of -68.3%. The company is currently unprofitable.
Outset Medical, Inc. (OM) generated $-47 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Outset Medical, Inc. (OM) has a debt-to-equity ratio of 0.76. This indicates moderate leverage.
Outset Medical, Inc. (OM) reported earnings per share (EPS) of $-5.37 in its most recent fiscal year.
Outset Medical, Inc. (OM) has a return on equity (ROE) of -106.2%. A negative ROE may indicate losses or negative equity.
Outset Medical, Inc. (OM) has a 5-year average gross margin of 23.6%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 7 years of financial data for Outset Medical, Inc. (OM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Outset Medical, Inc. (OM) has a book value per share of $8.35, based on its most recent annual SEC filing.